openPR Logo
Press release

Insulin Biosimilars Market Volume Analysis, Segments, Value Share and Key Trends 2016-2026

01-25-2017 10:40 AM CET | Health & Medicine

Press release from: Future Market Insights

Insulin Biosimilars Market Volume Analysis, Segments, Value

A new race has been initiated between biosimilar and branded drug manufacturers to gain maximum revenue share from insulin market. The upcoming three years are very crucial for insulin manufacturers, as most of the branded insulin are going to be off patent which would results into the loss of around US$53 Bn revenue for branded manufacturers in 2016. Generic manufacturers are expected to take smaller chunk of this amount owing to their local presence which would restrain them take share from other markets. In such dynamic situation, the original drug manufacturers are seeking for plan B to sustain their hold in the market. As a result, these companies are now integrated with biosimilar manufacturers through agreement, alliance. Moreover, legal troubles pertaining patent infringement is hampering the development insulin Biosimilars. In order to overcome such infringement issues, the companies are now collaborating with each other to develop biosimilars versions of insulin. Recent example of global collaboration agreement between Mylan N.V. and Momenta Pharmaceuticals, Inc. has provided a competitive advantage to Mylan by increasing the number of insulin biosimlars under development. This collaboration will capitalized Mylan’s existing portfolio of biologics and insulin analog development.

Insulin Biosimilars Market: Drivers and Restraints

Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1883

Insulin Biosimilars Market: Segmentation

The global market for insulin Biosimilar is segmented on the basis of disease indication and geography.

On the basis of disease indication, the global insulin Biosimilar market is segmented as,

Type I Diabetes

Type II Diabetes

Insulin Biosimilars Market: Overview

Development of clinically proven insulin Biosimilar will pave the road for new entrants. The upcoming patent expiration of blockbuster insulin drugs will open a new avenue and unprecedented opportunities for biosimilar development and manufacturing companies. The cost of insulin biosimilar is currently high owing to stringent adherence requirements in terms of complex regulations and manufacturing and operations. Prices of biosimilar drugs are expected decreased by an average of 20% as compared to branded drugs.

Insulin Biosimilars Market: Region-wise Outlook

Geographically, the global insulin biosimilar market is segmented into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan, Japan, Middle East and Africa. Among all the regions, North America will continue to lead the global market for insulin biosimilars market due to high demand for insulin. Europe insulin market is expected to account for second largest share in global market primarily due to early approval for biosimilar which is expected to fuel the market growth. Asian companies are competing on the basis of price and has patient pool suffering diabetes. Hence, the Asia Pacific insulin biosimilar market is expected to witness fastest growth in overall market over the forecast period.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1883

Insulin Biosimilars Market: Key Players

Key players operating in the global insulin biosimilar market are Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., Pfizer Inc., Biocon, Mylan N.V. and others

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
press@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insulin Biosimilars Market Volume Analysis, Segments, Value Share and Key Trends 2016-2026 here

News-ID: 421478 • Views:

More Releases from Future Market Insights

Workstation Software Market to Soar to USD 43.9 Billion by 2035, Fueled by 3D Modeling and VR Innovation
Workstation Software Market to Soar to USD 43.9 Billion by 2035, Fueled by 3D Mo …
Rising Demand for Workstation Software Across Industries The global workstation software market is set for robust growth, driven by increasing demand for advanced visualization, simulation, and design tools across industries such as manufacturing, architecture, media, and entertainment. Valued at USD 14.8 billion in 2025, the market is projected to reach USD 43.9 billion by 2035, registering a compound annual growth rate (CAGR) of 11.5%. This surge reflects the rising complexity of
Bean Flour Market Set for Robust Growth in the USA at 6.27% CAGR Through 2035
Bean Flour Market Set for Robust Growth in the USA at 6.27% CAGR Through 2035
The global bean flour market is entering a period of remarkable expansion, driven by surging demand for plant-based nutrition and gluten-free alternatives. Analysts forecast the market to grow from USD 5,075.3 million in 2025 to USD 9,262.0 million by 2035, reflecting a CAGR of 6.2%. This trajectory highlights an unparalleled opportunity for manufacturers to address evolving consumer preferences while enhancing sustainability and profitability. As the world shifts towards cleaner diets and
Blueberry Ingredient Market Set to Soar with 6.27% Growth in the USA by 2035
Blueberry Ingredient Market Set to Soar with 6.27% Growth in the USA by 2035
The blueberry ingredient industry has firmly established itself as a cornerstone of the functional foods, nutraceuticals, and natural flavoring sectors. Analysts project the market valuation to reach approximately USD 2.8 billion by 2025, with a robust CAGR of 6.5% forecasted from 2025 to 2035. This growth is being fueled by the escalating demand for clean-label products, plant-based formulations, and functional solutions across the food, beverage, and cosmetic industries. Click Here for
Activated Cake Emulsifier Market Set for 6.27% Growth in the USA, Poised to Transform Baking Innovation by 2035
Activated Cake Emulsifier Market Set for 6.27% Growth in the USA, Poised to Tran …
The activated cake emulsifier market is entering a transformative phase, driven by evolving consumer preferences toward premium, high-quality bakery products. Estimated to reach USD 1,343.2 million in 2025, the market is projected to achieve USD 2,360.5 million by 2035, representing a robust 5.8% CAGR over the next decade. This growth offers a strategic opportunity for manufacturers to meet rising consumer demands while future-proofing operations through innovation, regional customization, and sustainability. Click

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of